Researchers from the Icahn School of Medicine at Mount Sinai, in collaboration with the Clinical Proteomic Tumor Analysis Consortium of the National Institutes of Health, The University of Texas MD Anderson Cancer Center, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and others, have unveiled a detailed understanding of immune responses in cancer, marking a significant development in the field.
Roche’s Vabysmo challenges Eylea dominance with third European indication – Pharmaceutical Technology
Vabysmo notched $2.66bn in global sales in 2023. Image credit: Shutterstock/ Marlon Trottmann. The European Commission (EC) has approved Roche’s Vabysmo (faricimab) for the treatment
July 30, 2024